What’s a good way to put a dent in rare diseases? Well, you can always throw $23 million at it. At least that’s what the FDA did this past week. Through the Orphan Products Clinical Trials Grants Program, 21 new clinical trial research grants were awarded to studies developing drugs and devices for 21 different diseases. And they’re not just hoping that something good will come out of it, they have proof that it works. Five studies that received funding from this grants program supported product approvals in 2015 alone. If they keep this up, one day rare diseases will be extinct. And with names like lymphangioleiomyomatosis (try saying that three times fast), who needs ‘em? That’s just being pretentious.